No Data
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
Why CRISPR Therapeutics (CRSP) Soared on Friday?
Citi Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Cuts Target Price to $82
CRISPR Therapeutics Up Over 16%, on Pace for Largest Percent Increase Since April 2023 -- Data Talk
CRISPR Upped to Outperform by Evercore on Upcoming Data
Express News | CRISPR Therapeutics Shares Are Trading Higher After Evercore ISI Upgraded the Stock From In-Line to Outperform and Raised Its Price Target From $60 to $99. Also, Morgan Stanley Raised Its Price Target From $30 to $32
